Current Report Filing (8-k)
23 3월 2016 - 6:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): March 22, 2016
ROCK CREEK PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
000-15324
(Commission File Number)
|
52-1402131
(IRS Employer Identification No.)
|
|
|
|
|
2040 Whitfield Avenue, Suite 300
Sarasota, Florida 34243
(Address of principal executive offices,
including zip code)
844-727-0727
(Registrant’s telephone number,
including area code)
Not Applicable
(Former name or former address, if changed
since last report)
|
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On March 22, 2016, Rock Creek Pharmaceuticals,
Inc. (the “Company”) issued a press release announcing its financial results for the 2015 fiscal year. A copy of the
press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Item
2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. This information will
not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except to the extent that the registrant specifically incorporates it by reference.
Item 9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release, dated March 22, 2016
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ROCK CREEK PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Michael J. Mullan
|
|
|
Michael J. Mullan
|
|
|
Chairman of the Board and Chief Executive Officer
|
Date: March 22, 2016
Rock Creek Pharmaceuticals (CE) (USOTC:RCPIQ)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Rock Creek Pharmaceuticals (CE) (USOTC:RCPIQ)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Rock Creek Pharmaceuticals Inc (CE) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Rock Creek Pharmaceuticals, Inc. News Articles